The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Ivabradine is an effective treatment for postural tachycardia syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome

NCT03182725

Postural Orthostatic Tachycardia Syndrome

COMPLETED PHASE3

Crossover Study of Propranolol vs Ivabradine in POTS

NCT04186286

Postural Tachycardia Syndrome

RECRUITING PHASE2

Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia

NCT01657136

Inappropriate Sinus Tachycardia

COMPLETED PHASE3

Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease

NCT01768585

Coronary Artery Disease Coronary Arteriosclerosis

UNKNOWN PHASE4

Cardiovascular Effects of Selective I(f)-Channel Blockade

NCT00865917

Postural Orthostatic Tachycardia Syndrome

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postural Tachycardia Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ivabradine

Ivabradine 10 mg once

Group Type ACTIVE_COMPARATOR

ivabradine

Intervention Type DRUG

placebo

Group Type PLACEBO_COMPARATOR

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ivabradine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with POTS by the following criteria:

1. The presence of characteristic orthostatic symptoms of the POTS for at least six months.
2. An increase in the heart rate of at least 30 beats per minute (without concomitant significant decrease in blood pressure of more than 20/10 mmHg) within 10 minutes after assuming a standing position (or during tilt test) on at least 3 separate occasions.
3. No other concomitant diseases that could explain the symptoms of POTS.

Exclusion Criteria

1. History of systemic illness capable of affecting of affecting autonomic function (eg, diabetes mellitus, SLE).
2. History of cardiovascular disease.
3. History of smoking, drug or alcohol abuse.
4. Pregnancy, and also uncontrolled thyroid or adrenal disorders.
5. Using any drug metabolized by cytochrome P450 3A4 enzyme during the last 72 hours.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No